BioSpace News Archive

MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics™), today announced a groundbreaking partnership with the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN) to participate in a multicenter randomized clinical trial substudy of its PocketECG® technology.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today a decision from InEK in Germany that Revita has been granted Status 1 designation under its NUB funding process.

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS ® T Cells.

Intrommune Therapeutics, Inc. today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy.

Neuvivo today announced the expansion of its Advisory Board, adding James Kovach, MD, JD as a new member.

Schrödinger announced that management will provide a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference.

In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition to full year 2022 guidance.

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva ® .

Techdow USA Inc. (“Techdow USA”), a vertically integrated generic injectables company, today announced the launch of its Heparin Sodium Injection, USP in the US market.

Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference.